<SEC-DOCUMENT>0001193125-17-219039.txt : 20170630
<SEC-HEADER>0001193125-17-219039.hdr.sgml : 20170630
<ACCEPTANCE-DATETIME>20170630081755
ACCESSION NUMBER:		0001193125-17-219039
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20170628
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20170630
DATE AS OF CHANGE:		20170630

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			HELIUS MEDICAL TECHNOLOGIES, INC.
		CENTRAL INDEX KEY:			0001610853
		STANDARD INDUSTRIAL CLASSIFICATION:	ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			WY
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-55364
		FILM NUMBER:		17940417

	BUSINESS ADDRESS:	
		STREET 1:		SUITE 400, 41 UNIVERSITY DRIVE
		CITY:			NEWTOWN
		STATE:			PA
		ZIP:			18940
		BUSINESS PHONE:		215-809-2018

	MAIL ADDRESS:	
		STREET 1:		SUITE 400, 41 UNIVERSITY DRIVE
		CITY:			NEWTOWN
		STATE:			PA
		ZIP:			18940
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d411240d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES
AND EXCHANGE COMMISSION </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT STYLE="white-space:nowrap">8-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT
REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Section&nbsp;13 or 15(d) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>June&nbsp;30, 2017 (June 28, 2017) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g411240cover.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>HELIUS MEDICAL TECHNOLOGIES, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>WYOMING</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">000-55364</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">36-4787690</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(State or other jurisdiction</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Commission</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(I.R.S. Employer</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>of incorporation or organization)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>File Number)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Identification No.)</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in charter) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Suite 400, 41 University Drive </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Newtown, Pennsylvania, 18940 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive offices) (Zip Code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code: (215) <FONT STYLE="white-space:nowrap">809-2018</FONT> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <FONT STYLE="white-space:nowrap">8-K</FONT> filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this
chapter) or Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Securities Exchange Act of 1934 <FONT STYLE="white-space:nowrap">(&#167;240.12b-2</FONT> of this chapter). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&nbsp;&nbsp;&#9746; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange
Act&nbsp;&nbsp;&#9746; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;7.01&nbsp;Regulation FD Disclosure </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&nbsp;28, 2017, Helius Medical Technologies, Inc. (the &#147;Company&#148;) issued a press release announcing the closing of a CAD
$7.0&nbsp;million (US$ 5,275,900) private placement. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> (this &#147;Report&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information in this Report, including Exhibit 99.1 hereto, is furnished pursuant to Item 7.01 and shall not be deemed &#147;filed&#148;
for purposes of Section&nbsp;18 of the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the
Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. The Company&#146;s submission of this Report shall not be deemed an admission as to the materiality of any information
required to be disclosed solely to satisfy the requirements of Regulation FD. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Report and Exhibit 99.1 hereto contain forward-looking
statements within the meaning of the federal securities laws. These forward looking statements are based on current expectations and are not guarantees of future performance. Further, the forward-looking statements are subject to the limitations
listed in Exhibit 99.1 and in the other reports of the Company filed with the Securities and Exchange Commission, including that actual events or results may differ materially from those in the forward-looking statements. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>Item&nbsp;9.01.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Financial Statements and Exhibits. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(d)&nbsp;Exhibits </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:28.45pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit<BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:66.80pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit&nbsp;Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release, dated June&nbsp;28, 2017</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>HELIUS MEDICAL TECHNOLOGIES, INC.</B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated: June&nbsp;30, 2017</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Joyce LaViscount</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Joyce LaViscount, Chief Financial Officer</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d411240dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g411240ex.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Helius Medical Announces Closing of CAD$7.0 Million </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Private Placement </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NEWTOWN, PA &#150;
June</B><B></B><B>&nbsp;27, 2017 &#150; Helius Medical Technologies, Inc. (TSX: HSM and HSM.WT and OTCQB: HSDT) (&#147;Helius&#148; or the &#147;Company&#148;),</B>&nbsp;a medical technology company focused on the treatment of neurological symptoms
caused by disease or trauma, is pleased to announce that it has completed a <FONT STYLE="white-space:nowrap">non-brokered</FONT> private placement (the &#147;<B>Private Placement</B>&#148;) of 4,000,000 shares of Class&nbsp;A Common Stock (the
&#147;<B>Shares</B>&#148;) at a price of CAD$1.75 (US$1.32) per Share for aggregate gross proceeds of CAD$7,000,000 (US$ 5,275,900). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The net proceeds of
the Private Placement will be used by the Company for submissions to the U.S. Food and Drug Administration, the launch of a clinical trial investigating the PoNS&#153; Therapy for the rehabilitation of chronic symptoms multiple sclerosis patients
and for general corporate purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All Shares issued pursuant to the Private Placement are subject to a hold period under applicable Canadian securities
laws, which will expire four months plus one day from the date of closing of the Private Placement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Shares issued under the Private Placement have
not been, and will not be, registered under the United States Securities Act of 1933, as amended (the &#147;<B>U.S. Securities Act</B>&#148;), or any state securities laws, and accordingly, are &#147;restricted securities&#148; for U.S. securities
law purposes. Such shares may not be offered or sold within the United States except in compliance with the registration requirements of the U.S. Securities Act and applicable state securities requirements or pursuant to exemptions therefrom, such
as Rule 144 of the U.S. Securities Act, which will first permit sales in the United States beginning six months after the date of closing of the Private Placement. The Shares may not be the subject of hedging transactions unless such transactions
are conducted in compliance with the U.S. Securities Act. This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the Company&#146;s securities in the United States. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About PoNS&#153; Therapy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Portable Neuromodulation Stimulator (PoNS) is an investigational <FONT STYLE="white-space:nowrap">non-invasive</FONT> device designed to deliver
neurostimulation through the tongue. PoNS Therapy combines the use of the device with physical or cognitive therapy and is currently being evaluated in a multicenter clinical trial for the treatment of balance disorder for subjects with mild to
moderate Traumatic Brain Injury. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Helius Medical Technologies, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Helius Medical Technologies is a medical technology company focused on neurological wellness. Helius seeks to develop, license and acquire unique and <FONT
STYLE="white-space:nowrap">non-invasive</FONT> platform technologies that amplify the brain&#146;s ability to heal itself. For more information, please visit <U>www.heliusmedical.com</U>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cautionary Disclaimer Statement: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain statements in
this news release are not based on historical facts and constitute forward-looking statements or forward-looking information within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws
(&#147;<B>forward-looking statements</B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All statements other than statements of historical fact included in this news release are
forward-looking statements that involve risks and uncertainties. Such forward-looking statements include, among others, statements regarding the expected use of proceeds from the Private Placement and the business objectives of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Forward-looking statements are often identified by terms such as &#147;will&#148;, &#147;may&#148;, &#147;should&#148;, &#147;anticipate&#148;,
&#147;expects&#148; and similar expressions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There can be no assurance that such statements will prove to be accurate and actual results and future
events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company&#146;s expectations include the necessity of conducting successful clinical testing to
establish safety and effectiveness of the PoNS Therapy for human performance improvement, the requirement for regulatory approval for marketing for human performance improvement prior to the Company&#146;s ability to commercialize the PoNS Therapy
for such indications, and other risks detailed from time to time in the filings made by the Company with securities regulators. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The reader is cautioned
that assumptions used in the preparation of any forward-looking statements may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks,
uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking statement. Such information, although considered reasonable by management at the time
of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
release are expressly qualified by this cautionary statement. Risks and uncertainties about the Company&#146;s business are more fully discussed in the Company&#146;s Transition Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> for the period ended December&nbsp;31, 2016, which has been filed with the United States Securities and Exchange Commission and the Canadian securities regulators and which can be obtained from either at
www.sec.gov or www.sedar.com, and the Company&#146;s other filings with the SEC and Canadian securities regulators from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The forward-looking
statements contained in this news release are made as of the date of this news release and the Company assumes no obligation to update any forward-looking statement or to update the reasons why actual results could differ from such statements except
to the extent required by law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"># # # </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CONTACT </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor Relations</B>: Josh Berg </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">415-205-7891</FONT></FONT> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">info@heliusmedical.com </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Media Contact: </B>Becky Kern </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">914-772-2310</FONT></FONT> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">bkern@heliusmedical.com </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g411240cover.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g411240cover.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M\M6HSHRY9H^LHUH5H\T&5/B-_P A+2O^P=%_-J]NKM#T1PX#:?\ B9C^$/\
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MI;EFMHB\9C<H"4+;BIQTSWI 24 % !0 4 % !0 4 % !0 4 % !0 4 % !0
(4 % !0!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g411240ex.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g411240ex.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M^)KZO _[O ^0Q_\ O,_4UZ[#B"@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * /.?'W_(=@_P"O9?\ T)J^<S7^,O3]6?391_ ?K^B.5KRSUC<\5W=Q
M8>$/#]U:RM#/'(Y5U.".M>_!N.&IM'CTH1GBZT9*Z-CPE\1;;5=EEJI2VO.B
MR=$D_P #^G\J[*.)4M);G#B\NE2]^EJOQ1WE=AY(4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % 'G/C[_D.P?]>R_P#H35\YFO\ &7I^K/ILH_@/U_1'
M*UY9ZQJ^-O\ D1M"_P"NC_UKWH_[K3/)P_\ OE4\YZ5D>F>U?"_4+N_\.3"Z
MG:7R)_+C+<D+M!QG\:]3"R;AJ?-9G3C"LN56NCK=2F>VTJ\GB.V2.%W4XS@A
M2174>6<-X'\4ZOK6O26M]<B2%86< 1JO(('8>],#T.D!Y[XX\4ZOHNNQ6UC<
MB.%H5<@QJW))'<>PI@=OI<TESI-G/*<R20(['&,DJ":0%N@ H P?&=Q-:^$[
MV:WE>*50F'1L$?..] &%\-=0O+ZWU W=U-.49-OF.6Q][IFF!G*?%G_"7@'^
MT?L'VWT;9Y>_\L8H ],I % !0 4 % !0 4 ><^/O^0[!_P!>R_\ H35\YFO\
M9>GZL^FRC^ _7]$<K7EGK&KXV_Y$;0O^NC_UKWH_[K3/)P_^^53SFLCTSV'X
M2?\ (NWO_7T?_0%KTL)\#]3YW-OXL?0[/6?^0'J'_7O)_P"@FNP\@\P^&7_(
MTS?]>S_^A+38'KE(#R3XG?\ (SP?]>R_^A-30'HME>P:=X4L[NY<)#%:1LQ_
MX"*0'!77Q!US4KMH]&M-B#[JK'YCD>IZ_P J8%G1OB+>0WXM-=@"J3M,@3:R
M'W%%@.G\<D-X,OF4@@A""._SK2 Y[X5?\>VI_P"]'_[-38"CQKJO_":?V3B#
M[-]L\G[AW;=^.N>N* +_ (W\4ZAX>N;2.R$165"6WKGH?K0!TNAWDNH:)9WD
MVWS9H@[;1@9-(#E/&GB[4M U:&VLQ"8WA#G>F3G)'K[4P.F&KQVOAJ+5KT@#
M[.DK[1U) X'U)Q2 \_D\>^(M2N)#I5GB)/X8XC(0/<__ *J8&IX:\=:E?:M%
MI=_8!I7;;NC&TIZD@_\ UJ /0*0'G/C[_D.P?]>R_P#H35\YFO\ &7I^K/IL
MH_@/U_1'*UY9ZQJ^-O\ D1M"_P"NC_UKWH_[K3/)P_\ OE4\YK(],]A^$G_(
MNWO_ %]'_P! 6O2PGP/U/G<V_BQ]#L]9_P"0'J'_ %[R?^@FNP\@\-T>'59K
MYUT?S_M 0D^2Q4[<C/3MTIB-W^S_ !U_>U+_ +_-_C0,PM8AU:"^1=8\_P"T
M; 5\YBQVY..O;.:!'9>-[UXO"&@V2L0LT*NV.^U%Q_Z%0,O>"M7\/Z+H$:S7
MT4=W*2\N5.>O Z>G\S0!D?$*^T;5!:W>GW4<MRI*2;002O4$\=N?SH U)+Q[
MWX0,[G+(JQ_@L@ _3% #?A5_Q[:G_O1_^S4,#G1_R4__ +B7_M2@#7^*G_'[
MIW_7-OYT(#N/"O\ R*NF?]<%_E2 \^^*'_(Q6O\ U[+_ .A-30'4ZSI]QJ7P
MWMX;92\JVT+A!U8 #(_*D!R/@OQA!X>BEL;VW;R9)-_F(/F4X Y'<<4P/3=/
MN=+U5AJ-DT,T@79YJ@;U!['N.G0T@-"@#C_&7A^ZU"5+^U'F&.,(T8'S8!)R
M/7K7CYCA9U&JD-;+8]K+,73I)TIZ7>YP#*5)4C!':O /HC4\;?\ (C:%_P!=
M'_K7O1_W6F>3A_\ ?*IYS61Z9[#\)/\ D7;W_KZ/_H"UZ6$^!^I\[FW\6/H=
MGK/_ " ]0_Z]Y/\ T$UV'D'F'PR_Y&F;_KV?_P!"6FP/7*0'DGQ._P"1G@_Z
M]E_]":F@+GCBS>3PGX?O%!*Q0JC>VY%(_P#030!+X/\ #7AW7=$266)C=QDK
M,!*1WX./3']: -NX\#>%;1%:X0Q*S!5+SD9)Z"D OB?2[71_ %[9V:%(5VD
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M'K^CWC3:+<&5/X6CD\MP/0\C^=,!8/!'B76;I'UFY:.->K2R^8P'L 3_ $H
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H?)'.<\T 2W6AWMQ]C\M+.V>!5 FC9_,B .2%/\0([''?K0!TE '_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
